Observational Study of Elizaria® in aHUS Patients

Locations (8)

Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" of the Ministry of Health of the Russian Federation

Kazan', Russia

Regional State Budgetary Healthcare Institution "Krasnoyarsk' Regional Clinical Center for Maternity and Childhood Protection"

Krasnoyarsk, Russia

State budgetary healthcare institution of the city of Moscow "Children's City Clinical Hospital of St. Vladimir of the Healthcare Department of the City of Moscow"

Moscow, Russia

Federal State Autonomous Educational Institution of Higher Education "First Moscow State Medical University n.a. I.M. Sechenov" of the Ministry of Health of the Russian Federation

Moscow, Russia

State budgetary healthcare institution of the City of Moscow "City clinical hospital #52 of the Moscow City Healthcare Department"

Moscow, Russia

State budgetary healthcare institution of the city of Moscow "City Clinical Hospital n.a. A.K. Eramishantsev of the Moscow City Healthcare Department"

Moscow, Russia

Key Dates

Start Date

December 19, 2019

Primary Completion Date

February 28, 2022

Completion Date

April 30, 2022

Last Updated

August 4, 2022

Observational Study of Elizaria® in aHUS Patients

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

National Registry of Rare Kidney Diseases

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy